Posaconazole to prevent fungal infections after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are getting a stem cell transplant for a blood cancer or blood disorder
- You have at least one high-risk factor, like a donor who is not a perfect match or a previous stem cell transplant
- You have not had a fungal infection in the past
- Your heart, lungs, kidneys, and liver are working well enough
- You are not pregnant and will use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
This trial tests if giving the antifungal drug posaconazole as a tablet can prevent serious fungal infections in people who have had a stem cell transplant and develop gut graft-versus-host disease (GVHD), which is a complication where donor cells attack the digestive tract. It may help protect patients who need strong immune-suppressing treatment for GVHD.
This study looks at how much posaconazole stays in your body while you receive it to prevent fungal infections during chemotherapy or after a stem cell transplant. Your care team will use standard posaconazole treatment and may take extra blood samples to understand its levels.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This trial tests whether posaconazole, given through a vein or by mouth, can treat invasive fungal infections in children under 2 years old. It may help improve outcomes for infants with hard-to-treat fungal disease.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.